Highlights Celltrion, Inc.

Equities

A068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 2025-01-22			5-day change	1st Jan Change
180,500.00 ^KRW	+0.45%		-0.11%	-3.73%

Jan. 14	Celltrion Unveils Strategic Vision for Advancing Its Innovative Drug Pipeline At the 43Rd Annual J.P. Morgan Healthcare Conference	CI
Jan. 09	Celltrion to Unveil Drug Development Plans at JP Morgan Conference	MT

Highlights

Celltrion Unveils Strategic Vision for Advancing Its Innovative Drug Pipeline At the 43Rd Annual J.P. Morgan Healthcare Conference	Jan. 14	CI
Celltrion to Unveil Drug Development Plans at JP Morgan Conference	Jan. 09	MT
Celltrion, Inc. announces an Equity Buyback for 546,747 shares.	Dec. 26	CI
Celltrion, Inc. authorizes a Buyback Plan.	Dec. 26	CI
Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on November 21, 2024.	Dec. 18	CI
U.S. FDA Approves Celltrion's STEQEYMA® (Ustekinumab-Stba), a Biosimilar to Stelara® (ustekinumab)	Dec. 17	CI
Celltrion Establishes New Subsidiary Celltrion BioSolutions	Dec. 17	MT
Celltrion Declares Stock, Cash Dividends	Dec. 15	MT
European Medicines Agency's Human Use Committee Backs Approval for Celltrion Biosimilars	Dec. 15	MT
Health Canada Approves Celltrion's Asthma Biosimilar Omlyclo; Shares Rise 3%	Dec. 09	MT
Health Canada Approves Celltrion?s Omlyclo (CT-P39), the First and Only Omalizumab Biosimilar in Canada	Dec. 09	CI
Celltrion Begins Commercial Operation of Third Domestic Manufacturing Plant; Shares Jump 4%	Dec. 09	MT
Celltrion to Retire 3 Million Treasury Stock in January	Dec. 04	MT
South Korea's FTC Slaps KRW435 Million Fine on Celltrion for Unfair Business Practices	Dec. 03	MT
Celltrion Launches KRW100 Billion Share Buyback	Nov. 22	MT
Celltrion, Inc. announces an Equity Buyback for 583,431 shares.	Nov. 20	CI
Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on October 25, 2024.	Nov. 20	CI
Celltrion, Inc.'s Equity Buyback announced on October 25, 2024, has closed with 537,924 shares, representing 0.26% for KRW 94,709.84 million.	Nov. 18	CI
Celltrion Presents Additional Data from Phase III Randomized Controlled Trials to Further Support Biosimilarity for CT-41 (Biosimilar Candidate of Denosumab) and CT-P47 (Biosimilar Candidate of Tocilizumab) At American College of Rheumatology Convergence 2024	Nov. 18	CI
Celltrion to Acquire iQone Healthcare Switzerland in European Expansion Push	Nov. 14	MT
Celltrion, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Nov. 14	CI
Celltrion's Net Attributable Income Plunges 61% in Q3, Sales Up 31%	Nov. 10	MT
Celltrion's Zymfentra Gains Broad US Insurance Coverage with New PBM Agreement	24-10-29	MT
Celltrion's Zymfentra Monotherapy Shows Comparable Efficacy to Combo Therapy in IBD Study	24-10-29	MT
Celltrion to Carry Out Share Buyback to Boost Value	24-10-27	MT

Become a member to access more news.

100% Free Registration

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Celltrion, Inc.

Equities

A068270

KR7068270008

Biotechnology & Medical Research

Highlights

Filters